The voltage-dependent anion channel (VDAC), located in the mitochondrial outer membrane, functions as gatekeeper for the entry and exit of mitochondrial metabolites, and thus controls cross-talk between mitochondria and the cytosol. VDAC also serves as a site for the docking of cytosolic proteins, such as hexokinase, and is recognized as a key protein in mitochondria-mediated apoptosis. The role of VDAC in apoptosis has emerged from various studies showing its involvement in cytochrome c release and apoptotic cell death as well as its interaction with proteins regulating apoptosis, including the mitochondria-bound isoforms of hexokinase (HK-I, HK-II). Recently, the functional HK-VDAC association has shifted from being considered in a predominantly metabolic light to the recognition of its major impact on the regulation of apoptotic responsiveness of the cell. Here, we demonstrate that the HK-VDAC1 interaction can be disrupted by mutating VDAC1 and by VDAC1-based peptides, consequently leading to diminished HK anti-apoptotic activity, suggesting that disruption of HK binding to VDAC1 can decrease tumor cell survival. Indeed, understanding structure-function relationships of VDAC is critical for deciphering how this channel can perform such a variety of differing functions, all important for cell life and death. By expressing VDAC1 mutants and VDAC1-based peptides, we have identified VDAC1 amino acid residues and domains important for interaction with HK and protection against apoptosis. These include negatively-and positively-charged residues, some of which are located within β-strands of the protein. The N-terminal region of VDAC1 binds HK-I and prevents HK-mediated protection against apoptosis induced by STS, while expression of a VDAC Nterminal peptide detaches HK-I-GFP from mitochondria. These findings indicate that the interaction of HK with VDAC1 involves charged residues in several β-strands and in the N-terminal domain. Displacing HK, serving as the 'guardian of the mitochondrion', from its binding site on VDAC1 may thus be exploited as an approach to cancer therapy.
Introduction
It is now well established that mitochondria play a critical role in the regulation of apoptosis in mammalian cells by acting as reservoirs for apoptotic proteins. In response to various apoptotic stimuli, several apoptogenic factors, such as cytochrome c and Smac/DIABLO, are released from the intermembrane space of mitochondria into the cytoplasm, where they initiate the activation of downstream destructive programs, including the caspase cascade (reviewed in [1, 2] ). It remains unclear, however, how these apoptotic initiators cross the outer mitochondrial membrane (OMM) and are released into the cytosol. While some models predict that such release is facilitated by a swelling of the mitochondrial matrix and subsequent rupture of the OMM, other models suggest the formation of protein-conducting channels that are large enough to allow the passage of cytochrome c and other proteins into the cytosol, without compromising the integrity of the OMM [3] . The finding that cytochrome c can leak from intact mitochondria [4] supports these latter models. Accordingly, accumulating evidence indicates that the voltage-dependent anion channel (VDAC) is involved in the release of apoptogenic proteins via the OMM [5] [6] [7] [8] [9] [10] [11] [12] . It should be noted, however, that multiple routes to apoptosis, including VDAC-independent pathways, exist [13] .
VDAC lies at a crucial position in the cell, forming the main interface between the mitochondrial and cellular metabolisms. VDAC constitutes a major pathway by which metabolites, such as NAD + / NADH, ADP/ATP, succinate, citrate, and ions, such as Ca 2+ , are exchanged between the cytosol and mitochondria [9, 14, 15] . Although VDAC plays a major role in the physiological processes of solute and metabolite transport, it is also recognized as a key protein in mitochondria-mediated apoptosis. Indeed, several recent reviews have focused on VDAC as an essential player in apoptosis as well as on the contribution of VDAC to the function of mitochondria in cell life and death [5] [6] [7] [8] [9] [10] [11] [12] . VDAC, believed to participate in the release of cytochrome c and to interact with anti-and pro-apoptotic proteins, is considered a likely candidate for the OMM pore-forming protein [7, 10, 11, 16, 17] . In fact, various stimuli were shown to trigger apoptosis by modulation of VDAC, implicating VDAC1 as a component of the apoptosis machinery [10, 12, 16, [18] [19] [20] .
The role of VDAC in apoptosis also emerged from demonstrations of interactions between VDAC and proteins regulating apoptosis. In fact, the first such demonstration was documented 21 years ago in a study by Nakashima et al. [21] in which a form of hexokinase (HK), now known to be HK-II was shown to bind to VDAC in the OMM of a rapidly growing cancer cell line. Later many other studies demonstrated interactions of VDAC with the mitochondrial-bound isoforms of hexokinase, HK-I and HK-II and with proteins from the Bcl2 family [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . In particular, mammalian HK-I and HK-II were shown to bind to the OMM via interacting with VDAC [10, 11, 22, 23, [26] [27] [28] 34, 35] . By binding to VDAC, HK gains direct access to the mitochondrial ATP pool for phosphorylation of glucose [36] . Indeed, one of the signature phenotypes of highly malignant, poorly differentiated tumors is their remarkable propensity to utilize glucose at a much higher rate than normal cells, a property frequently dependent on the marked overexpression of HK [37] [38] [39] . HK thus lies at the apex of the glycolytic pathway that provides those metabolic intermediates required by the biosynthetic pathways on which a transformed cell places such heavy demand [40] .
Recently, however, the functional HK-VDAC association has shifted from being considered in a predominantly metabolic light to recognition of its major impact on the regulation of apoptotic responsiveness of the cell. Recent studies from our own and other groups have demonstrated that HK can inhibit apoptosis by binding to VDAC and preventing release of cytochrome c [11, 22, 23, 26, 28, 34] . Hence, controlling both bioenergetics and cell death, the HKmitochondria interaction has been considered as a target for anticancer drugs in recent years [11, [40] [41] [42] [43] . Two main classes of agents affect the HK-mitochondria association. The first class includes competitive and/or allosteric compounds, i.e. inhibitors of HK activity [11, [43] [44] [45] [46] . The second class includes compounds that compete with VDAC for HK binding, such as VDAC1-based peptides [41] , or with HK for VDAC binding sites, such as the peptide representing the Nterminal hydrophobic domain of HK, shown to effectively displace HK from VDAC [24, 28] .
In this study, we provide insight into the function of VDAC1 in apoptosis and into the regulation of mitochondria-mediated apoptosis, while characterizing the interaction of HK with VDAC and characterizing the protection against apoptosis HK affords.
Materials and methods

Materials
Poly-D-lysine (PDL), propidium iodide and staurosporine (STS) came from Sigma (St. Louis, MO). Mito-Tracker red dye CMXPos was from Molecular Probes, Invitrogen (Eugene, OR). Monoclonal anti-VDAC antibodies raised to the N-terminal region of VDAC1 came from Calbiochem-Novobiochem (Nottingham, UK), while rabbit polyclonal anti-VDAC antibodies, prepared against amino acids 150-250 of hVDAC1, were from Abcam. Monoclonal anticytochrome c antibodies were obtained from BD Biosciences Pharmingen (San Jose, CA). Monoclonal anti-GFP antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Horseradish peroxidase-conjugated anti-mouse antibodies were obtained from Promega (Madison, WI). Metafectene was purchased from Biotex (Munich, Germany). RPMI 1640 and DMEM growth media and the supplements, fetal calf serum (FCS), L-glutamine and penicillinstreptomycin, were purchased from Biological Industries (Beit Haemek, Israel). Blasticidin and Zeocin were purchased from InvivoGen (San Diego, CA). Puromycin was purchased from ICN Biomedicals (Eschwege, Germany).
Plasmids and site-directed mutagenesis
DNA encoding mVDAC1, the LP1, LP2, LP3 and LP4 peptides was generated and cloned into the tetracycline-inducible pcDNA4/TO vector (Invitrogen), as described previously [41] . The four VDAC1 loop-based peptides, LP1 to LP4, were flanked by a tryptophan zipper motif, i.e. the SWTWE amino acid sequence, at the N-terminus of the peptide and the KWTWK sequence at the C-terminus. The pcDNA3-HK-II and pcDNA3.1-HK-I plasmids were kindly provided by J.E. Wilson (Michigan State University). pEGFP-HK-I and pEGFP-HK-II, encoding GFP connected to the HK-I C-terminal, were generated as described [23] .
Cell culture
MCF7 represents a human breast carcinoma cell line, HEK-293 cells correspond to a transformed primary human embryonal kidney cell line, T-REx-293 cells are tetracycline repressor-expressing HEK-293 cells and HeLa cells are derived from cervix cancer. hVDAC1-shRNA T-REx-293 were grown in Dulbecco's modified Eagle's medium (Biological Industries), supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, (all from Biological Industries) and maintained in a humidified atmosphere, at 37°C with 5% CO 2 . hVDAC1-shRNA T-REx-293 cells stably expressing the pSUPERretro vector encoding shRNA-targeting hVDAC1 were transfected with plasmids pcDNA4/TO-mVDAC1, grown as described [18] for 76 to 96 h prior to a 5 h exposure to STS (1.25 μM). Over-expression of mVDAC1-or Δ(26)mVDAC1-pcDNA4/TO was induced by tetracycline (2.5 μg/ml) for 96-112 h and cell viability was analyzed by acridine orange (AcOr) and ethidium bromide (EtBr) staining, as described previously [34] . HEK-T cells were transiently co-transfected with plasmids pEGFP-HK-I and pcDNA/4TO-mVDAC1, or plasmids encoding LP1, LP3 or LP4 peptides, grown for 48 h with tetracycline (1 μg/ml) and then visualized by confocal microscopy.
Confocal microscopy
HEK-T cells (3 × 10 5 ) were grown on PDL-coated coverslips in a 60 mm dish and transfected with pEGFP-HK-I or other plasmids, as indicated in figure or table legends. After 48 h, cells were stained with MitoTracker red dye (15 nM), washed with PBS, fixed for 20 min with 4% paraformaldehyde and rinsed with PBS prior to imaging by confocal microscopy (Olympus 1X81).
Apoptosis analysis
Apoptosis was analyzed by acridine orange/ethidium bromide staining [34] or by propidium iodide PI uptake and FACS analysis.
2.6. Protein purification and single-channel recording and analysis mVDAC1 and E72Q-mVDAC1 were expressed in the Saccharomyces cerevisiae por1-mutant strain M22-2 [34] or purified from mitochondria [9] . HK-I was purified from rat brain mitochondria [22] . Reconstitution of purified native and E72Q-mVDAC1 into a planar lipid bilayer (PLB), channel recording, and analysis were carried out as described [47] .
Results
It has been shown that over-expression of human, murine, yeast or rice VDAC1 induces apoptotic cell death, regardless of cell type [18, 23, 34, 48] . On the other hand, the interaction of HK-I with VDAC and protection against cell death as induced by VDAC1 over-expression has been demonstrated in our previous studies [22, 23, 34, 41] . Table 1 summarizes the effects of HK-I over-expression on apoptotic cell death induced by native and various mVDAC1 mutants. HK-I-mediated protection against apoptosis was analyzed by expression of native or mutated mVDAC1 in U-937 cell, T-REx-293 or hVDAC1-shRNA T-REx-293 cells, the latter resenting cells suppressed for endogenous VDAC1 expression [18] , as well as in the same cell lines over-expressing HK-I. HK-I elicited protection against apoptosis induced by over-expression of native and some, but not other VDAC1 mutants. The latter group includes VDAC1 containing mutations at glutamates 65 and 72, aspartate 77, lysine 73, as well as glutamates 188 and 202. The locations of the various mutations in the VDAC1 sequences proposed to be involved in HK interaction are depicted in the previously proposed [15, 49] and recently presented [50] [51] [52] VDAC1 structural models shown in Fig. 1 .
The inability of HK-I to interact with E72Q-VDAC1 was also demonstrated by analyzing the effects of HK-I on the conductance of E72Q-mVDAC1 reconstituted into a planar lipid bilayer (PLB) (Fig. 2) . Purified recombinant native and E72Q-mVDAC1 were PLB-reconstituted and channel conductance, before and after addition of purified HK-I were recorded, as a function of the voltage applied (Fig. 2 ). Upon addition of HK-I to native mVDAC1, channel conductance was reduced at all voltages tested. On the other hand, HK-I had no effect on the conductance of E72Q-mVDAC1. These results suggest that E72 is essential for HK-I interaction with VDAC1 and/or modifying its conductance.
To demonstrate that HK-I does not interact with other VDAC1 mutants, we co-expressed E72Q-or E188Q-mVDAC1 and a HK-I-GFP fusion protein in HEK-T cells. Confocal fluorescence microscopy showed that HK-I-GFP fluorescence is punctuated in cells transiently expressing mVDAC1 (Fig. 3) . On the other hand, HK-I-GFP fluorescence in cells expressing either E72Q-or E188Q-mVDAC1 was diffused throughout the cytosol. These results indicate that HK-I does not bind to the mutated VDAC1, in agreement with HK inability to confer protection against cell death (Table 1) .
Based on these and previously published results [23, 34, 41] , we defined the domains and amino acid residues involved in stabilizing VDAC1 conformation interacting with HK-I (Fig. 1 ). These VDAC1 regions were expressed in HEK-T cells in the form of the loop-shaped peptides, LP1W, LP2W and LP4W (Fig. 4A) , and their effects on the HK-I-GFP interaction with mitochondria were analyzed (Fig. 4B) . Peptide LP3W served as a control peptide since it did not interact with HK-I and had no effect on HK-I-mediated protection against apoptosis [41] . Fig. 4B demonstrates that the peptides can modify HK-I-GFP cellular distribution by detaching mitochondria-bound HK-I. Confocal fluorescence microscopy showed that in control cells expressing HK-I-GFP, the fluorescence is punctuated, as expected for a mitochondrial distribution. On the other hand, HK-I-GFP fluorescence in cells expressing the LP1, to lesser extent the LP2 or LP4 peptides (but not peptide LP3) was diffused throughout the cytosol (Fig. 4B) . These results indicate that the expressed VDAC1-based peptide detach or prevent HK-I binding to the mitochondria.
The function of the N-terminal region of VDAC1 in the interaction with HK-I and cell death was demonstrated using an N-terminal truncated version of VDAC1 [Δ(26)VDAC1]. As shown in Fig. 5 , upon transfection of HEK-293, MCF7 or HeLa cells with mVDAC1, about 10-15% of the cells underwent apoptosis by the third day. This level was increased to 50% by day five (Fig. 5A ), due to VDAC1 overexpression (Fig. 5C) [8, 10, 18, 23, 34] . Apoptotic cell death was reflected as enhanced nuclear fragmentation, visualized by acridine orange/ethidium bromide staining (Fig. 5B) . By contrast, cells expressing Δ(26)mVDAC1 showed 8-15% apoptosis by day 3, a level that did not change by the fifth day of expression. It should be mentioned that these cells express endogenous hVDAC1, and although this VDAC represents about 40% and the N-terminal-truncated mVDAC1 60% of the VDAC pool (Fig. 5C ), the effect of the latter is dominant, suggesting that the mutant displays a dominant negative effect (see also [53] ).
Finally, not only VDAC1-based peptides can detach HK-I-GFP from its binding site in VDAC, but also chemicals such as clotrimazole (CTM), an anti-fungal azole derivative that, at high concentrations (e.g. 20 μM) has been shown to dissociate HK-II from mitochondria in several cell types [24, 28] . Here, we demonstrate the ability of CTM to detach mitochondria-bound HK-I-GFP. The punctuated HK-I-GFP fluorescence, co-localized with MitoTracker, a dye that specifically labels mitochondria in living cells, was converted to diffuse labeling of the cytosol and did not co-localize with MitoTracker in the presence of CTM (Fig. 6A) . CTM also induced cell death (Fig. 6B ).
Discussion
In this study, we addressed the function of VDAC1 in apoptotic cell death and in the regulation of apoptosis via interaction with anti-apoptotic proteins, in particular HK. We and others have explored the N-terminal of VDAC1 as a key element in apoptosis induction and addressed its involvement in apoptosis regulation by HK and Bcl2 [30, 53, 54] (and Fig. 6 ). This discussion will thus focus on the HK-VDAC interaction, an interaction sufficient to allow cells to evade apoptosis. Indeed, the notion that the abundant expression of HK-I and HK-II in most cancer cells occurs only to ensure energy supplies has changed, with HK having been defined as an important regulator of mitochondrial function in both normal and cancer cells [40, 43] . Hence, HK has become known as the 'guardian of mitochondria' and as such, displacing HK from its binding site in VDAC1 may be exploited as a cancer therapy approach. In experiment (I), U-937 cells were transfected with plasmid pcDNA3.1-HK-I and grown in the presence of 400 μg/ml neomycin, as described previously [23, 34] . , highlighting the amino acids mutated and the sequences used for peptides expression. The amino acids mutated in the N-terminus and other domains of VDAC1 are labeled in the previously proposed transmembrane topology (A) [15] and in the newly established structure (B) [50] [51] [52] . Green circled amino acids indicate that mutation of these amino acids eliminates HK-Imediated protection against cell death. Amino acids indicated in red squares, when mutated, had no effect on HK-I-mediated protection against apoptosis. The positions of the sequences of the five peptides (yellow-labeled), expressed as peptides and tested in this work, are illustrated.
VDAC1 domains interacting with HK-I and HK-II
The VDAC1 amino acid residues and domains involved in the interaction with HK-I or HK-II have recently been identified [23, 34, 41, 53] . Certain point mutations in VDAC1 prevented HK-I binding, resulting in HK-I being no longer able to prevent cytochrome c release and subsequent apoptosis in cells over-expressing such VDAC1 mutants ( [23, 34] and Table 1 ). These mutations include the charged glutamate residues 65 and 72, aspartate 77 and lysine 73, located in the same sequence region, and glutamate 188 and 202 found in another VDAC1 region. According to previously proposed VDAC1 membrane topology models [15, 49, 55] , most of the mutated amino acids listed above were predicated to be exposed to the cytosol. However, according to recently described NMR-based [50, 52] and Xray crystallography-based [51] VDAC1 structure, some but not all of these mutations are located in cytosolic-facing sequences (Fig. 1) . The E72Q mutation that interrupts the interaction between VDAC1 and HK was also found to induce increases in mitochondrial swelling and OXPHOS activity, as well as to reduce in mitochondrial membrane cholesterol levels [56] .
The N-terminal portion of VDAC1 has been shown to interact with HK-I, as channel conductance of N-terminal truncated VDAC1 was not modified by HK-I [53] . Accordingly, a synthetic peptide corresponding to the N-terminal region of VDAC1 both binds HK-I and prevents HK-Iand HK-II-mediated protection against apoptosis induced by STS [41, 53] . Expression of the N-terminal peptide was found to detach HK-I-GFP from mitochondria, supporting the interaction of HK-I with the N-terminal region of VDAC1 [41] . These findings indicate that the interaction of HK with VDAC1 involves charged residues in several β-strands and the N-terminal domain. Recent VDAC1 structural analysis suggests a conformational cross-talk between Glut 72 (Glu-73 when counting the first Met) and the N-terminal part of the VDAC1 [50] . By hydrogen/deuterium exchange coupled to NMR spectroscopy, it has been shown that the N-terminal portion of hVDAC1 (residues in β1-β4) possesses conformational instability and switches between different VDAC1 conformations [50] . Interestingly, the structural instability of the N-terminal part was found to be particularly influenced by Glu-73 [50] , which is required for HK-I-and HK-IImediated modification of channel conductance (Fig. 2 and [23,34] ). According to the recently established hVDAC1 3D-structure, Glu-73 points to the membrane to interrupt the amphipathic pattern in strand β4. Mutations that replace the charged Glu-73 with glutamine [23, 34] or valine [50] resulted in stabilization of the β1-β4 strands [50] . Such mutations abolished both ruthenium red (RuR)-and HK-Imediated inhibition of VDAC channel activity and RuR-and HK-Imediated protection against apoptosis [23, 34, 57] . Thus, in accord with a recent suggestion [50] , the conformational flexibility of the β-strands (β1-β4) is, in addition to the N-terminal region, important for voltage gating and for the interaction of VDAC1 with HK and RuR, both in vitro and in vivo.
It has been shown that HK interacts with the mitochondria through its N-terminal 12 amino acid hydrophobic sequence (MIAAQLLAYYFT) [28, 58, 59] . HK might interact thorough its N-terminal region with the amphipatic α-helix N-terminal portion of VDAC1.
On the other hand, the findings presented here indicate that the interaction of HK with VDAC1 involves charged residues. As a highly hydrophobic sequence, the N-terminal of HK cannot directly engage essential charged VDAC1 residues. VDAC1 charged residues may thus be involved in stabilizing the HK-binding VDAC1 conformation. However, the interaction of synthetic VDAC1-based peptides with HK ( [41] and Fig. 4) , suggests that sequences within these domains are involved in the interaction of VDAC1 with HK. This suggests that HK interacts with several domains of VDAC1, which may explain the detachment of HK by various compounds (see below).
The VDAC1-HK interaction can also apparently be regulated by Glu-6-P and multiple protein kinases (e.g. glycogen synthase kinase (GSK)-3beta [27] and protein kinase C (PKC)), resulting in phosphorylation of VDAC itself or of HK [60] . It was also recently shown that over-expression of HK stimulated VDAC phosphorylation through a PKCɛ-dependent pathway [61] . It should be noted, however, that VDAC phosphorylation has not been detected by others [62] .
Possible mechanisms by which the detachment of mitochondriabound HK could lead to cell death
The balance between cytosolic HK-I and mitochondria-bound HK is important in the regulation of glycolysis, depending on physiological conditions and variations in intracellular distribution that could serve as a regulatory mechanism [63, 64] . The association between increased HK expression and cell survival is well demonstrated [22, 23, 28, 34, 41, 64, 65] . Several mechanisms have been proposed for how HK-I and HK-II promote tumor cell survival and anti-apoptotic defense, all involving interaction with VDAC1. HK bound to VDAC on the mitochondrial surface provides both a metabolic benefit and apoptosis-suppressive capacity that gives the cell a growth advantage and increases its resistance to chemotherapy [40] . Mitochondria-bound HK-I and HK-II have direct access to mitochondrial sources of ATP and greater affinity for MgATP supplied by mitochondria [66, 67] . In addition, HK bound to the cytosolic face of VDAC acts as a gate, regulating channel ion conductivity ( Fig. 2 and [22] ). Moreover, mitochondria-bound HK-I is also less sensitive to inhibition by Glu-6-P (CI 50 of 5 mM, compared with 0.1 mM for the soluble form of the enzyme) [22] . Thus, disruption of the HK-VDAC interaction should interfere with the energy balance of highly demanding cancer cells.
HK-I and HK-II over-expression in cells growing in tissue culture protects against cell death [22, 23, 27, 34, 41, 68] . The anti-apoptotic effect of HK is mediated through its binding to VDAC, preventing cytochrome c release by closing the mitochondrial release pore [22] or/and by preventing Bax translocation to the mitochondria and subsequent apoptosis [28] . Moreover, it has been shown that dissociation of HK from mitochondria induces cytochrome c release and apoptosis, even in cells deficient for both Bak and Bax [24] . Thus, if, as suggested, HK-VDAC interaction lies at the heart of apoptosis regulation by HK, interfering with HK binding to VDAC could form the basis for novel cancer treatment.
The mechanism(s) by which HK dissociation from mitochondria leads to apoptosis is not clear. Several possible mechanisms may be considered. As presented above, detachment of mitochondria-bound HK affects mitochondrial and overall cellular bioenergetics. Indeed, agents known to detach mitochondrial HK also induce ATP depletion preceding the decrease in cell viability [69, 70] . Another possible mechanism involves the high sensitivity of cytosolic HK to its product, Glu-6-P. Inhibiting HK activity by Glu-6-P would thus reduce energy production for high energy-demanding cancer cells. In addition, HK-I was shown to inhibit PTP opening [22, 71] , while Glu-6-P favored PTP opening [22, 68] , presumably by detaching HK from its binding site [22, 46] . Thus, high levels of Glu-6-P not only inhibit HK catalytic activity but also promote PTP opening, and thereby, induction of apoptosis. In addition, as pointed out above, HK-I and HK-II binding to VDAC is decreased by high concentrations of Glu-6-phosphate, leading to their release, thereby allowing for activation of apoptosis [22, 72, 73] . Another possible mechanism involves the regulation of ROS production by HK. It had been shown that mitochondrial HK activity fulfilled a key role as a preventive anti-oxidant against oxidative stress, reducing mitochondrial ROS generation through an ADP-recycling mechanism [74] . Expression of HK-II was found to protect against oxidant-induced cell death [75] , while HK-I over-expression in an established epithelial cell line leads to protection against oxidationinduced cell death [76] . It was also demonstrated that HK-I and HK-II reduce intracellular levels of ROS [61] . In addition, while glucose increased the rate of oxygen consumption and reduced the rate of H 2 O 2 generation, Glu-6-P increased H 2 O 2 generation [74] . Thus, overexpression of mitochondria-bound HKI and HKII protects cells against damage from oxidative stress. Accordingly, detachment of HK from its binding site in the mitochondria could lead to increased H 2 O 2 generation, thereby activating cell death. These findings suggest that mitochondrial HK activity is pivotal for the physiological functions of mitochondria.
Another possible mechanism for cell death induced by disruption of HK-VDAC complex may involve an interaction of Bax with the mitochondria. The HK-VDAC interaction changes the susceptibility of mitochondria to pro-apoptotic signals mediated through Bcl2-family proteins, such as Bax [28] . One of the proposed models by which Bax would mediate cytochrome c release from mitochondria involves the formation of a Bax/VDAC complex [77, 78] . It has been shown that VDAC-bound HK renders cells much more resistant to activation of apoptosis by Bax or Bak [28, 79] . It has also suggested that Bax and Bid may promote apoptosis by displacing HK from VDAC [28, 79] . For this activity, the C-terminal of Bax is required since Bax-ΔC was unable to displace HK or liberate cytochrome c from the reconstituted HK-VDAC-ANT (adenine nucleotide translocase) complex [80] . Accordingly, displacement of HK from its binding site in VDAC, by either means, would permit the actions of Bax/Bak in mediating apoptosis.
Regardless of the exact mechanism by which dissociation of HK from mitochondria promotes apoptosis, the results presented here strongly suggest that mitochondria-bound HK plays a critical role in mammalian mitochondrial-dependent apoptosis.
Disruption of the HK-VDAC interaction as an approach to cancer therapy
One of the major hallmarks of tumor cells is their relative resistance against cell death, owing to over-expression of antiapoptotic proteins of the Bcl2 family and HK [38, 39, [81] [82] [83] . As discussed above, it has been shown that a HK-VDAC1 interaction prevents induction of apoptosis in tumor-derived cells [22, 23, 26, 28, 34, 41, 58] . Thus, promoting detachment of HK from VDAC may be a promising cancer therapy strategy. Several compounds have been shown to induce dissociation of HK from the mitochondria and apoptosis. These include peptides corresponding to the amino terminus of both HK-I [58] and HK-II [28] , clotrimazole ( [28, 84] and Fig. 6 ), a cell permeable peptide corresponding to the amino-terminal 23 residues of HK-II fused to six arginines at the carboxyl-terminus (N-HK-II) [79] , methyl jesmonate [85] and VDAC1-based peptides ( [41] and Fig. 4) . The VDAC1-based peptides interacted with purified HK-I, detached HK bound to mitochondria isolated from tumor cells and in cells displaced mitochondria-bound HK-I-GFP ( [41] and Fig. 4 ).
These findings suggest that interfering with the binding of HK to mitochondria by VDAC1-based peptides may offer a novel strategy by which to augment apoptosis and enhance the synergistic therapeutic efficacy of conventional chemotherapeutic agents and reducing doselimiting toxicity.
HK-inhibiting compounds, including glucose metabolites, 2-deoxyglucose, oxamate and 3-bromopyruvate, selectively induce apoptosis in cancer cells and in pre-clinical models of cancer showed selective toxicity against tumor cells metabolizing anaerobically [43, [86] [87] [88] . These agents act to kill cancer cells by interacting with HK, however, whether these compounds detach HK from its binding sites in the mitochondria is still not clear. It is, nonetheless, proposed that these drugs are likely to enhance the efficacy of the current standard cancer chemotherapeutics and radiation regimens.
Recently [85] , we have shown that a plant stress hormone of the jasmonate family, methyl jasmonate (MJ), binds to HK in a specific manner, leading to its detachment from mitochondria isolated from several cancer cell types. The susceptibility of cancer cells to jasmonates is dependent on the expression of HK. This finding, thus, provides an explanation for the selective effects of jasmonates on cancer cells. It should be noted that intra-arterial injection of 3-bromopyruvate, an inhibitor of mitochondria-bound HK, into tumors implanted in rabbit liver killed up to 90% of the tumor cells without significant damage to the surrounding healthy tissue [86] .
To conclude, this and other studies discussed here strongly indicate that HK and VDAC are key components in the regulation of apoptosis and that the protective effects of HK against cell death are mediated via its direct interaction with VDAC. Furthermore, these results suggest that HK over-expression in cancer cells not only assures an adequate supply of energy, but also corresponds to an anti-apoptotic defense mechanism. Accordingly, interfering with HK binding to VDAC can serve to guide development of a new selective approach for cancer therapy.
